[Form 4] Jazz Pharmaceuticals, Inc. Insider Trading Activity
Jennifer E. Cook, a director of Jazz Pharmaceuticals (JAZZ), reported equity activity involving restricted stock units and a share sale on Form 4. The filing shows a grant of 3,507 restricted stock units under the company's director award plan; each unit represents a contingent right to one ordinary share and the units vest in full on July 24, 2026 subject to continuous service and plan conditions. Following that grant the reported beneficial ownership rose to 12,642 ordinary shares.
The filing also discloses a sale of 1,805 shares at a price of $111.2494 described as shares sold to satisfy tax obligations arising from vesting of previously granted restricted stock units, leaving 10,837 shares beneficially owned by the reporting person after the sale.
Jennifer E. Cook, membro del consiglio di amministrazione di Jazz Pharmaceuticals (JAZZ), ha comunicato operazioni sul capitale tramite un Modulo 4. La segnalazione riporta l'assegnazione di 3,507 unit脿 di azioni vincolate nell'ambito del piano di premi per i direttori; ogni unit脿 rappresenta il diritto condizionato a una azione ordinaria e le unit脿 maturano integralmente il 24 luglio 2026, soggette a servizio continuativo e alle condizioni del piano. Dopo questa assegnazione, la partecipazione beneficiaria dichiarata 猫 salita a 12,642 azioni ordinarie.
Il documento dichiara inoltre la vendita di 1,805 azioni al prezzo di $111.2494, indicata come vendita per soddisfare obblighi fiscali derivanti dalla maturazione di unit脿 di azioni vincolate precedentemente concesse, lasciando al dichiarante 10,837 azioni di propriet脿 beneficiaria dopo la vendita.
Jennifer E. Cook, directora de Jazz Pharmaceuticals (JAZZ), inform贸 movimientos sobre su participaci贸n mediante un Formulario 4. El informe registra la concesi贸n de 3,507 unidades de acciones restringidas bajo el plan de premios para directores; cada unidad equivale a un derecho contingente a una acci贸n ordinaria y las unidades vencen en su totalidad el 24 de julio de 2026, condicionado al servicio continuo y a los t茅rminos del plan. Tras esa concesi贸n, la propiedad beneficiaria informada aument贸 a 12,642 acciones ordinarias.
El informe tambi茅n revela la venta de 1,805 acciones a un precio de $111.2494, descrita como venta para satisfacer obligaciones fiscales derivadas del vencimiento de unidades de acciones restringidas previamente otorgadas, quedando al informante 10,837 acciones de propiedad beneficiaria despu茅s de la operaci贸n.
Jazz Pharmaceuticals(JAZZ)鞚� 鞚挫偓 Jennifer E. Cook鞚� Form 4鞐愳劀 歆�攵� 瓯半灅 雮挫棴鞚� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 鞚挫偓 氤挫儊 瓿勴殟鞐� 霐半澕 3,507臧滌潣 鞝滍暅鞝� 欤检嫕 雼渼臧� 攵�鞐悳 瓴冹溂搿� 雮橅儉雮╇媹雼�; 臧� 雼渼電� 氤错喌欤� 1欤检棎 雽�頃� 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃橂┌, 瓿勳啀 攴茧 氚� 瓿勴殟 臁瓣贝鞚� 於╈”頃� 瓴届毎 2026雲� 7鞗� 24鞚�鞐� 鞝勲秬 氩犾姢韺呺惄雼堧嫟. 頃措嫻 攵�鞐� 鞚错泟 氤搓碃 雽�靸侅瀽鞚� 鞁れ 氤挫湢電� 12,642欤�搿� 歃濌皜頄堨姷雼堧嫟.
鞁犼碃靹滌棎電� 霕愴暅 1,805欤�臧� 欤茧嫻 $111.2494鞐� 毵る弰霅� 靷嫟鞚� 瓿店皽霅橃柎 鞛堧姅雿�, 鞚措姅 鞚挫爠鞐� 攵�鞐悳 鞝滍暅鞝� 欤检嫕 雼渼鞚� 氩犾姢韺呾溂搿� 氚滌儩頃� 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暅 毵る弰霛缄碃 靹る獏霅橃柎 鞛堨溂氅�, 毵る弰 頉� 氤搓碃鞛愳潣 鞁れ 氤挫湢電� 10,837欤�鞛呺媹雼�.
Jennifer E. Cook, administratrice de Jazz Pharmaceuticals (JAZZ), a d茅clar茅 des op茅rations sur titres via un formulaire 4. Le d茅p么t indique l'attribution de 3 507 unit茅s d'actions restreintes dans le cadre du plan de r茅compenses pour administrateurs ; chaque unit茅 repr茅sente un droit conditionnel 脿 une action ordinaire et les unit茅s seront int茅gralement acquises le 24 juillet 2026, sous r茅serve de service continu et des conditions du plan. 脌 la suite de cette attribution, la d茅tention b茅n茅ficiaire d茅clar茅e est pass茅e 脿 12 642 actions ordinaires.
Le d茅p么t r茅v猫le 茅galement la vente de 1 805 actions au prix de $111.2494, d茅crite comme une vente destin茅e 脿 couvrir des obligations fiscales li茅es 脿 l'acquisition d'unit茅s d'actions restreintes pr茅alablement attribu茅es ; apr猫s cette vente, la personne d茅clarante d茅tient 10 837 actions en propri茅t茅 b茅n茅ficiaire.
Jennifer E. Cook, Direktorin von Jazz Pharmaceuticals (JAZZ), meldete Aktienvorg盲nge in einer Form 4. Die Einreichung weist die Gew盲hrung von 3.507 Restricted Stock Units im Rahmen des Director-Award-Plans aus; jede Unit berechtigt bedingt zum Bezug einer Stammaktie, und die Units vesten am 24. Juli 2026 vollst盲ndig, vorbehaltlich fortlaufender Dienstzeit und der Bedingungen des Plans. Nach dieser Zuteilung stieg das gemeldete wirtschaftliche Eigentum auf 12.642 Stammaktien.
Die Meldung gibt zudem den Verkauf von 1.805 Aktien zu einem Preis von $111.2494 an, beschrieben als Verkauf zur Begleichung steuerlicher Verpflichtungen, die durch das Vesting zuvor gew盲hrter Restricted Stock Units entstanden sind; nach dem Verkauf verbleiben beim Melder 10.837 Aktien wirtschaftliches Eigentum.
- 3,507 RSUs granted to a non-employee director, aligning her financial interests with shareholders
- Vesting schedule provided (units vest in full on July 24, 2026), giving transparency on timing
- 1,805 shares sold to satisfy tax obligations, reducing reported beneficial ownership from 12,642 to 10,837 shares
- Sale price disclosed ($111.2494), indicating a realized disposition rather than only grant activity
Insights
TL;DR: Director received 3,507 RSUs and sold 1,805 shares to cover taxes; net holdings remain disclosed.
The Form 4 details a standard non-employee director equity award and a contemporaneous sell-to-cover transaction. The 3,507 RSU grant is a typical alignment mechanism for non-employee directors, with vesting contingent on continued service and specified conditions. The reported 1,805-share sale at $111.2494 is explicitly described as tax-related, not presented as a discretionary liquidity event. Net beneficial ownership moves from 12,642 to 10,837 shares, reflecting those two reported entries. For investors, this filing documents management alignment and routine tax-driven selling rather than a strategic divestiture.
TL;DR: Governance signal: director compensation via RSUs and an administrative sell-to-cover are disclosed; no governance red flags in the filing.
The filing shows the issuer used its 2007 Amended and Restated Non-Employee Directors Stock Award Plan to grant RSUs that vest on a specified future date, which is standard practice to align outside directors with shareholder interests. The explanatory footnote clearly states the sale was to satisfy tax obligations from prior vesting, a common administrative step. There are no disclosures of accelerated vesting, loans, pledges, or derivative transactions here. From a governance perspective, the document contains routine equity compensation and tax-related disposition activity only.
Jennifer E. Cook, membro del consiglio di amministrazione di Jazz Pharmaceuticals (JAZZ), ha comunicato operazioni sul capitale tramite un Modulo 4. La segnalazione riporta l'assegnazione di 3,507 unit脿 di azioni vincolate nell'ambito del piano di premi per i direttori; ogni unit脿 rappresenta il diritto condizionato a una azione ordinaria e le unit脿 maturano integralmente il 24 luglio 2026, soggette a servizio continuativo e alle condizioni del piano. Dopo questa assegnazione, la partecipazione beneficiaria dichiarata 猫 salita a 12,642 azioni ordinarie.
Il documento dichiara inoltre la vendita di 1,805 azioni al prezzo di $111.2494, indicata come vendita per soddisfare obblighi fiscali derivanti dalla maturazione di unit脿 di azioni vincolate precedentemente concesse, lasciando al dichiarante 10,837 azioni di propriet脿 beneficiaria dopo la vendita.
Jennifer E. Cook, directora de Jazz Pharmaceuticals (JAZZ), inform贸 movimientos sobre su participaci贸n mediante un Formulario 4. El informe registra la concesi贸n de 3,507 unidades de acciones restringidas bajo el plan de premios para directores; cada unidad equivale a un derecho contingente a una acci贸n ordinaria y las unidades vencen en su totalidad el 24 de julio de 2026, condicionado al servicio continuo y a los t茅rminos del plan. Tras esa concesi贸n, la propiedad beneficiaria informada aument贸 a 12,642 acciones ordinarias.
El informe tambi茅n revela la venta de 1,805 acciones a un precio de $111.2494, descrita como venta para satisfacer obligaciones fiscales derivadas del vencimiento de unidades de acciones restringidas previamente otorgadas, quedando al informante 10,837 acciones de propiedad beneficiaria despu茅s de la operaci贸n.
Jazz Pharmaceuticals(JAZZ)鞚� 鞚挫偓 Jennifer E. Cook鞚� Form 4鞐愳劀 歆�攵� 瓯半灅 雮挫棴鞚� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 鞚挫偓 氤挫儊 瓿勴殟鞐� 霐半澕 3,507臧滌潣 鞝滍暅鞝� 欤检嫕 雼渼臧� 攵�鞐悳 瓴冹溂搿� 雮橅儉雮╇媹雼�; 臧� 雼渼電� 氤错喌欤� 1欤检棎 雽�頃� 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃橂┌, 瓿勳啀 攴茧 氚� 瓿勴殟 臁瓣贝鞚� 於╈”頃� 瓴届毎 2026雲� 7鞗� 24鞚�鞐� 鞝勲秬 氩犾姢韺呺惄雼堧嫟. 頃措嫻 攵�鞐� 鞚错泟 氤搓碃 雽�靸侅瀽鞚� 鞁れ 氤挫湢電� 12,642欤�搿� 歃濌皜頄堨姷雼堧嫟.
鞁犼碃靹滌棎電� 霕愴暅 1,805欤�臧� 欤茧嫻 $111.2494鞐� 毵る弰霅� 靷嫟鞚� 瓿店皽霅橃柎 鞛堧姅雿�, 鞚措姅 鞚挫爠鞐� 攵�鞐悳 鞝滍暅鞝� 欤检嫕 雼渼鞚� 氩犾姢韺呾溂搿� 氚滌儩頃� 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暅 毵る弰霛缄碃 靹る獏霅橃柎 鞛堨溂氅�, 毵る弰 頉� 氤搓碃鞛愳潣 鞁れ 氤挫湢電� 10,837欤�鞛呺媹雼�.
Jennifer E. Cook, administratrice de Jazz Pharmaceuticals (JAZZ), a d茅clar茅 des op茅rations sur titres via un formulaire 4. Le d茅p么t indique l'attribution de 3 507 unit茅s d'actions restreintes dans le cadre du plan de r茅compenses pour administrateurs ; chaque unit茅 repr茅sente un droit conditionnel 脿 une action ordinaire et les unit茅s seront int茅gralement acquises le 24 juillet 2026, sous r茅serve de service continu et des conditions du plan. 脌 la suite de cette attribution, la d茅tention b茅n茅ficiaire d茅clar茅e est pass茅e 脿 12 642 actions ordinaires.
Le d茅p么t r茅v猫le 茅galement la vente de 1 805 actions au prix de $111.2494, d茅crite comme une vente destin茅e 脿 couvrir des obligations fiscales li茅es 脿 l'acquisition d'unit茅s d'actions restreintes pr茅alablement attribu茅es ; apr猫s cette vente, la personne d茅clarante d茅tient 10 837 actions en propri茅t茅 b茅n茅ficiaire.
Jennifer E. Cook, Direktorin von Jazz Pharmaceuticals (JAZZ), meldete Aktienvorg盲nge in einer Form 4. Die Einreichung weist die Gew盲hrung von 3.507 Restricted Stock Units im Rahmen des Director-Award-Plans aus; jede Unit berechtigt bedingt zum Bezug einer Stammaktie, und die Units vesten am 24. Juli 2026 vollst盲ndig, vorbehaltlich fortlaufender Dienstzeit und der Bedingungen des Plans. Nach dieser Zuteilung stieg das gemeldete wirtschaftliche Eigentum auf 12.642 Stammaktien.
Die Meldung gibt zudem den Verkauf von 1.805 Aktien zu einem Preis von $111.2494 an, beschrieben als Verkauf zur Begleichung steuerlicher Verpflichtungen, die durch das Vesting zuvor gew盲hrter Restricted Stock Units entstanden sind; nach dem Verkauf verbleiben beim Melder 10.837 Aktien wirtschaftliches Eigentum.
FAQ
Who filed this Form 4 for JAZZ?
What equity award was reported on the JAZZ Form 4?
When do the granted RSUs vest?
How many shares were sold and at what price?
What is the reporting person鈥檚 beneficial ownership after the transactions?
